Diagnosis of erythroid dysplasia by flow cytometry: a review

References

• Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–1228.
   PubMed Web of Science ®Google Scholar
• Zavras PD, Sinanidis I, Tsakiroglou P, et al. Understanding the continuum between high-risk myelodysplastic syndrome and acute myeloid Leukemia. Int J Mol Sci. 2023;24(5):5018.
   PubMed Web of Science ®Google Scholar
• Valent P. ICUS, IDUS, CHIP and CCUS: diagnostic criteria, separation from MDS and clinical implications. Pathobiology. 2019;86:30–38. doi: 10.1159/000489042
   PubMed Web of Science ®Google Scholar
• Ramos F, Fernández-Ferrero S, Suárez D, et al. Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leuk Res. 1999;23(3):283–290.
   PubMed Web of Science ®Google Scholar
• Font P, Loscertales J, Soto C, et al. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts. Ann Hematol. 2015;94(4):565–573.
   PubMed Web of Science ®Google Scholar
• Hodes A, Calvo KR, Dulau A, et al. The challenging task of enumerating blasts in the bone marrow. Semin Hematol. 2019;56(1):58–64.
   PubMed Web of Science ®Google Scholar
• Goasguen JE, Bennett JM, Bain BJ, et al. Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areas. Br J Haematol. 2018;182(4):526–533.
   PubMed Web of Science ®Google Scholar
• Ogawa S. Genetics of MDS. Blood. 2019;133(10):1049–1059. doi: 10.1182/blood-2018-10-844621
   PubMed Web of Science ®Google Scholar
• Kern W, Haferlach C, Schnittger S, et al. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome. Cancer. 2010;116(19):4549–4563.
   PubMed Web of Science ®Google Scholar
• Kern W, Bacher U, Haferlach C, et al. Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: a study on 804 patients. Cytom Part B Clin Cytom. 2015;88(3):154–164.
   PubMed Web of Science ®Google Scholar
• Kern W, Haferlach C, Schnittger S, et al. Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics. Haematologica. 2013;98(2):201–207.
   PubMed Web of Science ®Google Scholar
• Matarraz S, López A, Barrena S, et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom. 2010;78(3):154–168.
   PubMedGoogle Scholar
• Westers TM, van der Velden VHJ, Alhan C, et al. Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch working Party on flow cytometry in MDS. Leuk Res. 2012;36(4):422–430.
   PubMed Web of Science ®Google Scholar
• Porwit A, van de Loosdrecht AA, Bettelheim P, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet working group for flow cytometry in MDS. Leukemia. 2014;28(9):1793–1798.
   PubMed Web of Science ®Google Scholar
• Wang W, Khoury JD. Where diagnosis for myelodysplastic neoplasms (MDS) stands today and where it will go: the role of flow cytometry in evaluation of MDS. Cytom Part B Clin Cytom. 2023;104(1):12–14. doi: 10.1002/cyto.b.22110
   PubMed Web of Science ®Google Scholar
• Fajtova M, Kovarikova A, Svec P, et al. Immunophenotypic profile of nucleated erythroid progenitors during maturation in regenerating bone marrow. Leuk Lymphoma. 2013;54(11):2523–2530.
   PubMed Web of Science ®Google Scholar
• Mathis S, Chapuis N, Debord C, et al. Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia. 2013;27(10):1981–1987. doi: 10.1038/leu.2013.178
   PubMed Web of Science ®Google Scholar
• Rosenberg CA, Bill M, Rodrigues MA, et al. Exploring dyserythropoiesis in patients with myelodysplastic syndrome by imaging flow cytometry and machine‐learning assisted morphometrics. Cytom Part B Clin Cytom. 2021;100(5):554–567.
   PubMed Web of Science ®Google Scholar
• Wangen JR, Eidenschink Brodersen L, Stolk TT, et al. Assessment of normal erythropoiesis by flow cytometry: important considerations for specimen preparation. Int J Lab Hematol. 2014;36(2):184–196.
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood. 2001;98(4):979–987.
   PubMed Web of Science ®Google Scholar
• Loken MR, Shah VO, Dattilio KL, et al. Flow cytometric analysis of human bone marrow: I Normal Erythroid Development. Blood. 1987;69(1):255–263.
   PubMed Web of Science ®Google Scholar
• van Lochem EG, van der Velden VHJ, Wind HK, et al. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry. 2004;60B(1):1–13.
   Google Scholar
• Xu F, Wu L, He Q, et al. Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndromes. Intern Med J. 2012;42(4):401–411.
   PubMed Web of Science ®Google Scholar
• Duetz C, Van Gassen S, Westers TM, et al. Computational flow cytometry as a diagnostic tool in suspected‐myelodysplastic syndromes. Cytom Part a 2021. Cytometry Part A. 2021;99(8):814–824. doi: 10.1002/cyto.a.24360
   PubMed Web of Science ®Google Scholar
• Johansson U, Rolf N, Futhee N, et al. Erythroid side scatter: a parameter that improves diagnostic accuracy of flow cytometry myelodysplastic syndrome scoring. Cytom Part B Clin Cytom. Cytometry B Clin Cytom. 2023;104(2):151–161. doi: 10.1002/cyto.b.22067.
   PubMed Web of Science ®Google Scholar
• Chopra A, Pati H, Mahapatra M, et al. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches. Ann Hematol. 2012;91(9):1351–1362.
   PubMed Web of Science ®Google Scholar
• Westers TM, Cremers EMP, Oelschlaegel U, et al. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica. 2017;102:308–319. doi: 10.3324/haematol.2016.147835
   PubMed Web of Science ®Google Scholar
• Wu D, Wood BL, Dorer R, et al. Utility of flow cytometry for immunophenotyping double-hit lymphomas. Cytom Part B Clin Cytom. 2013;84:398–398. doi: 10.1002/cytob.21117
   PubMed Web of Science ®Google Scholar
• Eidenschink Brodersen L, Menssen AJ, Wangen JR, et al. Assessment of erythroid dysplasia by “difference from normal” in routine clinical flow cytometry work-up. Cytom Part B Clin Cytom. 2015;88:125–135. doi: 10.1002/cytob.21199
   PubMed Web of Science ®Google Scholar
• Cremers EMP, Westers TM, Alhan C, et al. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica. 2017;102(2):320–326.
   PubMed Web of Science ®Google Scholar
• Violidaki D, Axler O, Jafari K, et al. Analysis of erythroid maturation in the nonlysed bone marrow with help of radar plots facilitates detection of flow cytometric aberrations in myelodysplastic syndromes. Cytom Part B Clin Cytom. 2020;98(5):399–411.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta MG, Lunghi M, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2005;19(5):776–783.
   PubMed Web of Science ®Google Scholar
• Della PM, Malcovati L, Invernizzi R, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2006;20(4):549–555.
   PubMed Web of Science ®Google Scholar
• Kern W, Westers TM, Bellos F, et al. Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group. Cytom Part B Clin Cytom. 2023;104(1):51–65.
   PubMed Web of Science ®Google Scholar
• Laranjeira P, Rodrigues R, Carvalheiro T, et al. Expression of CD44 and CD35 during normal and myelodysplastic erythropoiesis. Leuk Res. 2015;39(3):361–370.
   PubMed Web of Science ®Google Scholar
• Raimbault A, Itzykson R, Willems L, et al. The fraction of CD117/c‐KIT‐expressing erythroid precursors predicts ESA response in low‐risk myelodysplastic syndromes. Cytom Part B Clin Cytom. 2019;96(3):215–222.
   PubMed Web of Science ®Google Scholar
• Oliveira M, Laranjeira P, Fortuna M, et al. CD43 and CD49d from the B‐cell chronic lymphoproliferative disorders diagnostic panel are useful to detect erythroid dysplasia. Cytom Part B Clin Cytom. 2019;96(5):417–425.
   PubMed Web of Science ®Google Scholar
• Hu J, Liu J, Xue F, et al. Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo. Blood. 2013;121(16):3246–3253.
   PubMed Web of Science ®Google Scholar
• Oelschlaegel U, Oelschlaeger L, von Bonin M, et al. Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: diagnostic power and prognostic impact. Cytom Part B Clin Cytom. 2023;104(2):141–150.
   PubMed Web of Science ®Google Scholar
• van de Loosdrecht AA, Westers TM, van de Loosdrecht AA. Cutting edge: flow cytometry in myelodysplastic syndromes. J Natl Compr Cancer Netw. 2013;11(7):892–902. doi: 10.6004/jnccn.2013.0106
   PubMed Web of Science ®Google Scholar
• Elkhader J, Elemento O. Artificial intelligence in oncology: From bench to clinic. Semin Cancer Biol. 2022;84:113–128. doi: 10.1016/j.semcancer.2021.04.013
   PubMed Web of Science ®Google Scholar
• Brinkman RR. Improving the rigor and reproducibility of flow cytometry‐based clinical research and trials through automated data analysis. Cytom Part A. 2020;97(2):107–112. doi: 10.1002/cyto.a.23883
   PubMed Web of Science ®Google Scholar
• Pedersen CB, Olsen LR. Algorithmic clustering of single-cell cytometry data—how unsupervised are these analyses really? Cytom Part a. Cytometry Part A. 2020;97(3):219–221. doi: 10.1002/cyto.a.23917
   PubMed Web of Science ®Google Scholar
• Duetz C, Bachas C, Westers TM, et al. Computational analysis of flow cytometry data in hematological malignancies: future clinical practice? Curr Opin Oncol. 2020;32(2):162–169.
   PubMed Web of Science ®Google Scholar
• Van Gassen S, Callebaut B, Van Helden MJ, et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytom Part A. 2015;87(7):636–645.
   PubMedGoogle Scholar
• Porwit A, Violidaki D, Axler O, et al. Unsupervised cluster analysis and subset characterization of abnormal erythropoiesis using the bioinformatic flow‐self organizing maps algorithm. Cytom Part B Clin Cytom. 2022;102(2):134–142.
   PubMed Web of Science ®Google Scholar
• Weiß E, Walter W, Meggendorfer M, et al. Identification of a specific immunophenotype associated with a consistent pattern of genetic mutations including SRFS2 and gene expression profile in MDS. Cytom Part B Clin Cytom. 2023;104(2):173–182.
   PubMed Web of Science ®Google Scholar
• Park S, Kosmider O, Maloisel F, et al. Dyserythropoiesis evaluated by the RED score and hepcidin: ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. Haematologica. 2019;104(3):497–504.
   PubMed Web of Science ®Google Scholar
• van de Loosdrecht AA, Alhan C, Bene MC, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica. 2009;94:1124–1134. doi: 10.3324/haematol.2009.005801
   PubMed Web of Science ®Google Scholar
• van der Velden VHJ, Preijers F, Johansson U, et al. Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—recommendations from the European LeukemiaNet. Cytom Part B Clin Cytom. 2023;104(1):15–26.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Kreuzer K-A, Soosapilla A, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European research Initiative on CLL (ERIC) & European Society for clinical cell analysis (ESCCA) harmonisation project. Cytometry B Clin Cytom. 2018;94(1):121–128.
   PubMed Web of Science ®Google Scholar
• Maecker HT, Rinfret A, D’Souza P, et al. Standardization of cytokine flow cytometry assays. BMC Immunol. 2005;6(1):13.
   PubMed Web of Science ®Google Scholar
• Johansson U, McIver‐Brown N, Cullen M, et al. The flow cytometry myeloid progenitor count: a reproducible parameter for diagnosis and prognosis of myelodysplastic syndromes. Cytom Part B Clin Cytom. 2023;104(2):115–127.
   PubMed Web of Science ®Google Scholar
• Streiner DL. Best (but oft-forgotten) practices: the multiple problems of multiplicity—whether and how to correct for many statistical tests. Am J Clin Nutr. 2015;102(4):721–728. doi: 10.3945/ajcn.115.113548
   PubMed Web of Science ®Google Scholar
• Kahneman D, Sibony O, Sunstein CR. Noise: a flaw in human judgment. Scotland: HarperCollins; 2021.
   Google Scholar